CytoMed Therapeutics (GDTC) Competitors $1.97 +0.07 (+3.63%) As of 09/5/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock GDTC vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CALAShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. CytoMed Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences CytoMed Therapeutics (NASDAQ:GDTC) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability. Is GDTC or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets CytoMed TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Do analysts prefer GDTC or ATNFW? CytoMed Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 160.42%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytoMed Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer GDTC or ATNFW? In the previous week, CytoMed Therapeutics' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment CytoMed Therapeutics Neutral 180 Life Sciences Neutral Which has better valuation and earnings, GDTC or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than CytoMed Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytoMed Therapeutics$50KN/A-$1.84MN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Do institutionals & insiders have more ownership in GDTC or ATNFW? 0.0% of CytoMed Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryCytoMed Therapeutics beats 180 Life Sciences on 5 of the 5 factors compared between the two stocks. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.18B$5.83B$9.93BDividend YieldN/A2.27%6.70%4.52%P/E RatioN/A21.1076.1526.11Price / SalesN/A466.44562.61123.62Price / CashN/A45.7236.9959.28Price / Book3.159.8711.486.09Net Income-$1.84M-$53.42M$3.29B$266.51M7 Day Performance-5.42%2.93%1.27%0.46%1 Month Performance3.78%9.85%7.94%4.59%1 Year Performance29.73%15.74%62.94%26.04% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics1.8016 of 5 stars$1.92+1.1%$5.00+160.4%+28.9%$0.00$50K0.00N/AGap DownATNFW180 Life SciencesN/A$0.20-6.3%N/A+2,104.5%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.25+8.1%N/AN/A$0.00$110.87K0.0040Positive NewsGap DownALVOWAlvotechN/A$1.07+2.9%N/A-54.9%$0.00$560.10M0.004Positive NewsGap UpHigh Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05+29.9%N/AN/A$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.14-8.8%N/AN/A$0.00$39.19M0.0070Positive NewsBTMDWbioteN/A$0.01-15.6%N/A-96.6%$0.00$199.07M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.02-22.7%N/A-86.3%$0.00N/A0.008News CoverageShort Interest ↓Gap UpCALACalithera BiosciencesN/A$0.00-50.0%N/A-99.5%$0.00N/A0.0060Gap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDTC) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GDTC Stock Alerts